Abstract

Aim: This study was carried out to determine the prevalence of human T cell lymphotropic virus I/II (HTLV I/II) among blood donors at the Federal Teaching Hospital Gombe (FTHG), North-eastern, Nigeria. Methods: A total of 355 blood donors were recruited at the hematology department of FTHG for a hospital based cross-sectional study and were screened/confirmed for HTLV I/II by ELISA and western blot methods. Results: Seroprevalence of HTLV I/II among the 355 participants with mean age of 30.77 years (±8.27) was 6.5% on screening with ELISA but confirmed to be 0% by western blot. Majority were males, 352 (99.2%) and mostly (45.9%) between 21–30 years of age. Donors for family replacements predominated (85.1%) with more than half (58.6%) being first time blood donors. Conclusion: This study reveals the absence of HTLV I/II among blood donors in Gombe North-eastern Nigeria. It also highlights the possibility of false positivity in some of the reported prevalence of HTLV I and II from some parts of Nigeria that were based on screening tests only. The importance of confirmatory testing in all research works on HTLV (including HTLV 3 and HTLV 4) is further strengthened with this study. There is however the need for a larger study and the use of molecular diagnostics to reconfirm this assertion.

Highlights

  • Human T cell lymphotropic virus I (HTLV-I) is the first human retrovirus to be discovered and has continued to be an important transfusion transmissible infection (TTI) especially in highly endemic regions such as the subSaharan Africa [1]

  • This study reveals the absence of human T cell lymphotropic virus (HTLV) I/II among blood donors in Gombe Northeastern Nigeria

  • The virus has been associated with several diseases including adult T cell leukemia (ATL), tropical spastic paraparesis, HTLV-I uveitis and HTLV-I associated infective dermatitis [2, 3]

Read more

Summary

Introduction

Human T cell lymphotropic virus I (HTLV-I) is the first human retrovirus to be discovered and has continued to be an important transfusion transmissible infection (TTI) especially in highly endemic regions such as the subSaharan Africa [1]. HTLV-II has not been causally linked to human malignancy but may be associated with lymphocytosis, increased risk of developing inflammatory neuropathies and infectious diseases [6]. Human T cell lymphotropic virus has been considered to be currently one of the greatest concerns threatening health of blood recipients in some endemic areas [8]. Blood transfusion related HTLV associated diseases develop more rapidly than with other means of transmission [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call